Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IN8bio, Inc. (INAB)
USD1.44
+0.06 (+4.35%)
US NASDAQ Healthcare Biotechnology
Address
350 5th Avenue 10118
New York City, NY, US
New York City, NY, US
CEO
Tai-Wei
Website
in8bio.com
IPO
2021-07-30
CIK 1740279 ISIN US45674E2081
Description
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.44
+0.06 (+4.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
58.2K
Beta
0.19
Float Shares
3.30M
Free Float %
71.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.54% | -3.61% | +18.52% | -10.11% | -2.44% | -31.62% | -66.67% | -97.83% | -99.47% | -99.47% | -99.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
1.44
Low
4.00
+177.8%
Consensus
4.00
+177.8%
Median
4.00
+177.8%
High
4.00
+177.8%
DCF (Unlevered)
5.49
+281.2%
DCF (Levered)
5.56
+285.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
4.00
+177.8%
|
| All Time | 1 |
4.00
+177.8%
|
Quality scores
Altman Z-Score
-7.99
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-679.0% Q1'26: -1,644.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-611.5% Q1'26: -659.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-91.8% ★ Q1'26: -94.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -0.12× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 9.20M (-100.0%)
|
47.67M
47.67M – 47.67M
+418.1% YoY
|
1.10M
1.10M – 1.10M
-97.7% YoY
|
10.88M
10.88M – 10.88M
+889.2% YoY
|
29.98M
29.98M – 29.98M
+175.5% YoY
|
56.33M
56.33M – 56.33M
+87.9% YoY
|
| EBITDA |
-26.94M
|
-17.36M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-29.60M
|
-19.86M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-30.44M
est: -904.94M (+96.6%)
|
-19.44M
est: -11.41M (-70.4%)
|
-5.44M
-6.49M – -4.38M
+52.3% YoY
|
-4.64M
-4.64M – -4.64M
+14.7% YoY
|
-3.55M
-4.69M – -2.40M
+23.5% YoY
|
-3.98M
-3.98M – -3.98M
-12.3% YoY
|
-1.18M
-1.18M – -1.18M
+70.3% YoY
|
| SGA |
12.64M
|
9.65M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.57
est: -16.90 (+96.6%)
|
-4.44
est: -2.61 (-70.3%)
|
-1.24
-1.48 – -1.00
+52.3% YoY
|
-1.06
-1.06 – -1.06
+14.7% YoY
|
-0.73
-1.07 – -0.55
+31.4% YoY
|
-0.91
-0.91 – -0.91
-25.2% YoY
|
-0.27
-0.27 – -0.27
+70.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
35.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 27-4413262 | 6.74M | 9.30% | 6.74M | — | 6.74M | — | OO | Maryland | 2024-10-09 | ↗ |
| 2 | Identification Nos. of above persons (. | 6.74M | 9.30% | 6.74M | — | 6.74M | — | IN | States | 2024-10-09 | ↗ |
| 3 | AARON GLENN LOUIS FLETCHER | 6.64M | 35.40% | — | 6.64M | — | 6.64M | IN | — | 2021-08-13 | ↗ |
| 4 | BIOS ADVISORS GP, LLC | 6.64M | 35.40% | — | 6.64M | — | 6.64M | OO | — | 2021-08-13 | ↗ |
| 5 | BIOS CAPITAL MANAGEMENT, LP | 6.64M | 35.40% | — | 6.64M | — | 6.64M | PN | — | 2021-08-13 | ↗ |
| 6 | CAVU ADVISORS, LLC | 6.64M | 35.40% | — | 6.64M | — | 6.64M | OO | — | 2021-08-13 | ↗ |
| 7 | CAVU MANAGEMENT, LP | 6.64M | 35.40% | — | 6.64M | — | 6.64M | PN | — | 2021-08-13 | ↗ |
| 8 | LESLIE WAYNE KREIS, JR. | 6.64M | 35.40% | — | 6.64M | — | 6.64M | IN | — | 2021-08-13 | ↗ |
| 9 | Transcend Partners Opportunity Fund I LLC | 4.11M | 13.00% | — | 4.11M | — | 4.11M | OO | — | 2023-08-11 | ↗ |
| 10 | BIOS EQUITY PARTNERS II, LP | 3.70M | 19.70% | — | 3.70M | — | 3.70M | PN | — | 2021-08-13 | ↗ |
| 11 | BIOS EQUITY PARTNERS III, LP | 2.93M | 15.60% | — | 2.93M | — | 2.93M | PN | — | 2021-08-13 | ↗ |
| 12 | William Tai-Wei Ho | 2.90M | 9.10% | 2.65M | 255.5K | 2.65M | 146.0K | IN | — | 2023-08-11 | ↗ |
| 13 | BIOS FUND III QP, LP | 2.23M | 11.90% | — | 2.23M | — | 2.23M | PN | — | 2021-08-13 | ↗ |
| 14 | BIOS FUND II QP, LP | 1.88M | 10.00% | — | 1.88M | — | 1.88M | PN | — | 2021-08-13 | ↗ |
| 15 | BIOS INCYSUS CO-INVEST I, LP | 997.4K | 5.30% | — | 997.4K | — | 997.4K | PN | — | 2021-08-13 | ↗ |
| 16 | BIOS FUND II, LP | 574.4K | 3.10% | — | 574.4K | — | 574.4K | PN | — | 2021-08-13 | ↗ |
| 17 | BIOS FUND III NT, LP | 359.4K | 1.90% | — | 359.4K | — | 359.4K | PN | — | 2021-08-13 | ↗ |
| 18 | BIOS FUND III, LP | 340.7K | 1.80% | — | 340.7K | — | 340.7K | PN | — | 2021-08-13 | ↗ |
| 19 | Emily Fairbairn | 287.4K | 0.90% | 196.1K | 91.3K | 196.1K | 91.3K | IN | — | 2023-08-11 | ↗ |
| 20 | BIOS FUND II NT, LP | 251.2K | 1.30% | — | 251.2K | — | 251.2K | PN | — | 2021-08-13 | ↗ |
| 21 | BIOS EQUITY PARTNERS, LP | 12.8K | 0.07% | — | 12.8K | — | 12.8K | PN | — | 2021-08-13 | ↗ |
| 22 | BP DIRECTORS, LP | 12.8K | 0.07% | — | 12.8K | — | 12.8K | PN | — | 2021-08-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
-21 vs prev Q
New positions
1
Closed positions
22
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | — -102.0 (-100.0%) | — -28.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 2 | BIOS CAPITAL MANAGEMENT, LP | — -286.7K (-100.0%) | — -622.1K (-100.0%) | 0.00% -0.007 pp | 0.00% -0.700 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 162.4K | 0.05% |
| 2 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | — | 0.22% |
| 3 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | — | 0.22% |
| 4 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | — | 0.22% |
| 5 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | — | 0.22% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | — | 0.03% |
| 7 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | — | 0.17% |
| 8 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | — | 0.17% |
| 9 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | — | 0.03% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | — | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
433.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+433,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-04 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,000 | 1.96 | 156.8K | 80,000 | D | ↗ |
| 2026-02-04 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 1.96 | 147.0K | 75,000 | D | ↗ |
| 2026-02-04 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 72,000 | 1.96 | 141.1K | 72,000 | D | ↗ |
| 2026-02-04 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 206,000 | 1.96 | 403.8K | 206,000 | D | ↗ |
| 2025-12-22 | Roemer Alan S. | Director | A-Award | A | Common Stock | 36,232 | 1.38 | 50.0K | 49,514 | D | ↗ |
| 2025-12-22 | Rochlin Kate | Officer | A-Award | A | Common Stock | 7,247 | 1.38 | 10.0K | 9,085 | D | ↗ |
| 2025-12-22 | McCall Patrick | Officer | A-Award | A | Common Stock | 7,247 | 1.38 | 10.0K | 9,482 | D | ↗ |
| 2025-12-22 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Common Stock | 36,232 | 1.38 | 50.0K | 121,168 | D | ↗ |
| 2025-12-22 | FAIRBAIRN EMILY | Director | A-Award | A | Common Stock | 724,637 | 1.38 | 1,000.0K | 724,637 | I | ↗ |
| 2025-12-22 | Brandt Peter C. | Director | A-Award | A | Common Stock | 72,464 | 1.38 | 100.0K | 95,181 | D | ↗ |
| 2025-05-08 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 63,150 | 0.17 | 10.7K | 63,150 | D | ↗ |
| 2025-05-08 | Greenwood Luba | Director | A-Award | A | Stock Option (right to buy) | 63,150 | 0.17 | 10.7K | 63,150 | D | ↗ |
| 2025-05-08 | Graff Jeremy R. | Director | A-Award | A | Stock Option (right to buy) | 63,150 | 0.17 | 10.7K | 63,150 | D | ↗ |
| 2025-05-08 | FAIRBAIRN EMILY | Director | A-Award | A | Stock Option (right to buy) | 63,150 | 0.17 | 10.7K | 63,150 | D | ↗ |
| 2025-05-08 | Epperly Corinne | Director | A-Award | A | Stock Option (right to buy) | 63,150 | 0.17 | 10.7K | 63,150 | D | ↗ |
| 2025-05-08 | Brandt Peter C. | Director | A-Award | A | Stock Option (right to buy) | 63,150 | 0.17 | 10.7K | 63,150 | D | ↗ |
| 2025-05-02 | Kreis Leslie W. | 10% Owner | P-Purchase | A | Pre-Funded Warrants | 1,148,482 | 0.00 | 114.85 | 2,431,763 | I | ↗ |
| 2025-05-01 | Ho William Tai-Wei | Director / Officer / 10% Owner | D-Return | D | Series A Warrants (right to buy) | 81,967 | 0.45 | 36.9K | 0 | D | ↗ |
| 2025-04-30 | Roemer Alan S. | Director | M-Exempt | A | Common Stock | 102,459 | 0.18 | 18.9K | 387,489 | D | ↗ |
| 2025-04-30 | Rochlin Kate | Officer | M-Exempt | D | Series A Warrants (right to buy) | 12,295 | 0.18 | 2.3K | 0 | D | ↗ |
| 2025-04-30 | McCall Patrick | Officer | M-Exempt | A | Common Stock | 15,000 | 0.18 | 2.8K | 67,071 | D | ↗ |
| 2025-04-30 | Brandt Peter C. | Director | M-Exempt | A | Common Stock | 81,967 | 0.18 | 15.1K | 681,538 | D | ↗ |
| 2025-04-27 | Roemer Alan S. | Director | D-Return | D | Series B Warrants (right to buy) | 102,459 | 1.50 | 153.7K | 0 | D | ↗ |
| 2025-04-27 | Rochlin Kate | Officer | A-Award | A | Series A Warrants (right to buy) | 12,295 | 0.18 | 2.3K | 12,295 | D | ↗ |
| 2025-04-27 | McCall Patrick | Officer | D-Return | D | Series B Warrants (right to buy) | 20,492 | 1.50 | 30.7K | 0 | D | ↗ |
| 2025-04-27 | Lamb Lawrence | Officer | A-Award | A | Series B Warrants (right to buy) | 1,639 | 0.45 | 737.55 | 1,639 | D | ↗ |
| 2025-04-27 | Ho William Tai-Wei | Director / Officer / 10% Owner | D-Return | D | Series B Warrants (right to buy) | 81,967 | 1.50 | 123.0K | 0 | D | ↗ |
| 2025-04-27 | Graff Jeremy R. | Director | A-Award | A | Series B Warrants (right to buy) | 2,049 | 0.45 | 922.05 | 2,049 | D | ↗ |
| 2025-04-27 | Epperly Corinne | Director | A-Award | A | Series B Warrants (right to buy) | 81,967 | 0.45 | 36.9K | 81,967 | D | ↗ |
| 2025-04-27 | Brandt Peter C. | Director | A-Award | A | Series B Warrants (right to buy) | 81,967 | 0.18 | 15.1K | 81,967 | D | ↗ |
| 2025-02-05 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 338,950 | 0.29 | 98.3K | 338,950 | D | ↗ |
| 2025-02-05 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 343,000 | 0.29 | 99.5K | 343,000 | D | ↗ |
| 2025-02-05 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 306,750 | 0.29 | 89.0K | 306,750 | D | ↗ |
| 2025-02-05 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 912,450 | 0.29 | 264.6K | 912,450 | D | ↗ |
| 2024-12-19 | Whitfill Travis | Director | A-Award | A | Stock Option (right to buy) | 42,676 | 0.24 | 10.2K | 42,676 | D | ↗ |
| 2024-12-19 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 93,242 | 0.24 | 22.4K | 93,242 | D | ↗ |
| 2024-12-19 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 302,839 | 0.24 | 72.7K | 302,839 | D | ↗ |
| 2024-12-19 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 290,085 | 0.24 | 69.6K | 290,085 | D | ↗ |
| 2024-12-19 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 286,899 | 0.24 | 68.9K | 286,899 | D | ↗ |
| 2024-12-19 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 1,188,282 | 0.24 | 285.2K | 1,188,282 | D | ↗ |
| 2024-12-19 | Greenwood Luba | Director | A-Award | A | Stock Option (right to buy) | 39,449 | 0.24 | 9.5K | 39,449 | D | ↗ |
| 2024-12-19 | Graff Jeremy R. | Director | A-Award | A | Stock Option (right to buy) | 47,697 | 0.24 | 11.4K | 47,697 | D | ↗ |
| 2024-12-19 | FAIRBAIRN EMILY | Director | A-Award | A | Stock Option (right to buy) | 31,559 | 0.24 | 7.6K | 31,559 | D | ↗ |
| 2024-12-19 | Epperly Corinne | Director | A-Award | A | Stock Option (right to buy) | 37,655 | 0.24 | 9.0K | 37,655 | D | ↗ |
| 2024-12-19 | Brandt Peter C. | Director | A-Award | A | Stock Option (right to buy) | 49,490 | 0.24 | 11.9K | 49,490 | D | ↗ |
| 2024-10-04 | Roemer Alan S. | Director | A-Award | A | Common Stock | 126,582 | 0.40 | 50.0K | 285,030 | D | ↗ |
| 2024-10-04 | Rochlin Kate | Officer | D-Return | D | Series A Warrants (right to buy) | 12,295 | 1.25 | 15.4K | 0 | D | ↗ |
| 2024-10-04 | McCall Patrick | Officer | D-Return | D | Series A Warrants (right to buy) | 20,492 | 1.25 | 25.6K | 0 | D | ↗ |
| 2024-10-04 | Kreis Leslie W. | 10% Owner | P-Purchase | A | Pre-Funded Warrants | 709,040 | 0.00 | 70.90 | 1,283,281 | I | ↗ |
| 2024-10-04 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Common Stock | 126,582 | 0.40 | 50.0K | 2,548,094 | D | ↗ |
| 2024-10-04 | Fletcher Aaron G.L. | 10% Owner | A-Award | A | Series A Warrant | 574,241 | 0.45 | 258.4K | 574,241 | I | ↗ |
| 2024-10-04 | FAIRBAIRN EMILY | Director | P-Purchase | A | Pre-Funded Warrants (right to buy) | 3,038,743 | 0.00 | 303.87 | 3,038,743 | I | ↗ |
| 2024-10-04 | Brandt Peter C. | Director | A-Award | A | Series C Warrants (right to buy) | 253,164 | 0.27 | 68.4K | 253,164 | D | ↗ |
| 2024-09-04 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.47 | 117.5K | 250,000 | — | ↗ |
| 2024-09-04 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.47 | 117.5K | 250,000 | — | ↗ |
| 2024-09-04 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.47 | 117.5K | 250,000 | — | ↗ |
| 2024-09-04 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 0.47 | 235.0K | 500,000 | — | ↗ |
| 2024-09-04 | Goswami Trishna | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.47 | 117.5K | 250,000 | — | ↗ |
| 2024-06-12 | Whitfill Travis | Director | A-Award | A | Stock Option (right to buy) | 33,650 | 1.47 | 49.5K | 33,650 | — | ↗ |
| 2024-06-12 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 33,650 | 1.47 | 49.5K | 33,650 | — | ↗ |
| 2024-06-12 | Greenwood Luba | Director | A-Award | A | Stock Option (right to buy) | 33,650 | 1.47 | 49.5K | 33,650 | — | ↗ |
| 2024-06-12 | Graff Jeremy R. | Director | A-Award | A | Stock Option (right to buy) | 33,650 | 1.47 | 49.5K | 33,650 | — | ↗ |
| 2024-06-12 | FAIRBAIRN EMILY | Director | A-Award | A | Stock Option (right to buy) | 33,650 | 1.47 | 49.5K | 33,650 | — | ↗ |
| 2024-06-12 | Epperly Corinne | Director | A-Award | A | Stock Option (right to buy) | 33,650 | 1.47 | 49.5K | 33,650 | — | ↗ |
| 2024-06-12 | Brandt Peter C. | Director | A-Award | A | Stock Option (right to buy) | 33,650 | 1.47 | 49.5K | 33,650 | — | ↗ |
| 2024-02-07 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 186,000 | 1.22 | 226.9K | 186,000 | — | ↗ |
| 2024-02-07 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 189,000 | 1.22 | 230.6K | 189,000 | — | ↗ |
| 2024-02-07 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 169,000 | 1.22 | 206.2K | 169,000 | — | ↗ |
| 2024-02-07 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 502,000 | 1.22 | 612.4K | 502,000 | — | ↗ |
| 2024-02-07 | Goswami Trishna | Officer | A-Award | A | Employee Stock Option (right to buy) | 176,000 | 1.22 | 214.7K | 176,000 | — | ↗ |
| 2024-02-07 | Epperly Corinne | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.22 | 15.3K | 12,500 | — | ↗ |
| 2023-12-13 | Roemer Alan S. | Director | A-Award | A | Series B Warrants (right to buy) | 102,459 | 1.50 | 153.7K | 102,459 | — | ↗ |
| 2023-12-13 | Rochlin Kate | Officer | A-Award | A | Series B Warrants (right to buy) | 12,295 | 1.50 | 18.4K | 12,295 | — | ↗ |
| 2023-12-13 | McCall Patrick | Officer | A-Award | A | Common Stock | 20,492 | 1.22 | 25.0K | 26,755 | — | ↗ |
| 2023-12-13 | Lamb Lawrence | Officer | A-Award | A | Common Stock | 1,639 | 1.22 | 2.0K | 101,369 | — | ↗ |
| 2023-12-13 | Kreis Leslie W. | 10% Owner | P-Purchase | A | Series B Warrant | 574,241 | 1.50 | 861.4K | 574,241 | — | ↗ |
| 2023-12-13 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Common Stock | 81,967 | 1.22 | 100.0K | 2,421,512 | — | ↗ |
| 2023-12-13 | Graff Jeremy R. | Director | A-Award | A | Series B Warrants (right to buy) | 2,049 | 1.50 | 3.1K | 2,049 | — | ↗ |
| 2023-12-13 | Goswami Trishna | Officer | A-Award | A | Series A Warrants (right to buy) | 4,098 | 1.25 | 5.1K | 4,098 | — | ↗ |
| 2023-12-13 | Fletcher Aaron G.L. | 10% Owner | P-Purchase | A | Pre-Funded Warrants | 574,241 | 0.00 | 57.42 | 574,241 | — | ↗ |
| 2023-12-13 | Epperly Corinne | Director | A-Award | A | Common Stock | 81,967 | 1.22 | 100.0K | 81,967 | — | ↗ |
| 2023-12-13 | Brandt Peter C. | Director | A-Award | A | Common Stock | 81,967 | 1.22 | 100.0K | 264,440 | — | ↗ |
| 2023-12-13 | Bios Clinical Opportunity Fund, LP | 10% Owner | — | D | Series B Warrant | 574,241 | 1.50 | 861.4K | 0 | — | ↗ |
| 2023-12-06 | Epperly Corinne | Director | A-Award | A | Stock Option (right to buy) | 54,800 | 1.04 | 57.0K | 54,800 | — | ↗ |
| 2023-09-13 | Graff Jeremy R. | Director | P-Purchase | A | Common Stock | 2,500 | 0.95 | 2.4K | 2,500 | — | ↗ |
| 2023-08-25 | McCall Patrick | Officer | P-Purchase | A | Common Stock | 1,000 | 1.03 | 1.0K | 6,263 | — | ↗ |
| 2023-08-24 | Ho William Tai-Wei | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 23,800 | 1.05 | 25.0K | 2,339,545 | — | ↗ |
| 2023-07-28 | FAIRBAIRN EMILY | Director | J-Other | D | Common Stock | 4,111,958 | 0.00 | — | 0 | — | ↗ |
| 2023-06-21 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 67,800 | 2.01 | 136.3K | 67,800 | — | ↗ |
| 2023-06-21 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 87,150 | 2.01 | 175.2K | 87,150 | — | ↗ |
| 2023-06-21 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 77,600 | 2.01 | 156.0K | 77,600 | — | ↗ |
| 2023-06-21 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 393,950 | 2.01 | 791.8K | 393,950 | — | ↗ |
| 2023-06-21 | Goswami Trishna | Officer | A-Award | A | Employee Stock Option (right to buy) | 134,000 | 2.01 | 269.3K | 134,000 | — | ↗ |
| 2023-06-15 | Whitfill Travis | Director | A-Award | A | Stock Option (right to buy) | 85,000 | 2.12 | 180.2K | 85,000 | — | ↗ |
| 2023-06-15 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 85,000 | 2.12 | 180.2K | 85,000 | — | ↗ |
| 2023-06-15 | Greenwood Luba | Director | A-Award | A | Stock Option (right to buy) | 85,000 | 2.12 | 180.2K | 85,000 | — | ↗ |
| 2023-06-15 | Graff Jeremy R. | Director | A-Award | A | Stock Option (right to buy) | 85,000 | 2.12 | 180.2K | 85,000 | — | ↗ |
| 2023-06-15 | FAIRBAIRN EMILY | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 85,000 | 2.12 | 180.2K | 85,000 | — | ↗ |
| 2023-06-15 | Brandt Peter C. | Director | A-Award | A | Stock Option (right to buy) | 85,000 | 2.12 | 180.2K | 85,000 | — | ↗ |
| 2023-05-01 | Graff Jeremy R. | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.74 | 47.0K | 27,000 | — | ↗ |
| 2023-04-14 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.22 | 244.0K | 200,000 | — | ↗ |
| 2023-04-14 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.22 | 244.0K | 200,000 | — | ↗ |
| 2023-04-14 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.22 | 244.0K | 200,000 | — | ↗ |
| 2023-04-14 | Ho William Tai-Wei | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 393,950 | 1.34 | 527.9K | 393,950 | — | ↗ |
| 2023-04-14 | Goswami Trishna | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.22 | 244.0K | 200,000 | — | ↗ |
| 2022-12-12 | Kreis Leslie W. | Director | P-Purchase | A | Common Stock | 57,052 | 2.48 | 141.4K | 3,727,597 | — | ↗ |
| 2022-12-12 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 57,052 | 2.48 | 141.4K | 3,727,597 | — | ↗ |
| 2022-10-21 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,555 | 0.00 | — | 60,555 | — | ↗ |
| 2022-10-21 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 59,796 | 0.00 | — | 59,796 | — | ↗ |
| 2022-10-21 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 62,826 | 0.00 | — | 62,826 | — | ↗ |
| 2022-10-21 | Ho William Tai-Wei | Officer | A-Award | A | Employee Stock Option (right to buy) | 83,265 | 0.00 | — | 83,265 | — | ↗ |
| 2022-10-21 | Goswami Trishna | Officer | A-Award | A | Employee Stock Option (right to buy) | 68,427 | 0.00 | — | 68,427 | — | ↗ |
| 2022-09-28 | Kreis Leslie W. | Director / 10% Owner | P-Purchase | A | Common Stock | 19,017 | 2.02 | 38.4K | 3,670,545 | — | ↗ |
| 2022-09-28 | Fletcher Aaron G.L. | Director / 10% Owner | P-Purchase | A | Common Stock | 2,913 | 2.02 | 5.9K | 561,989 | — | ↗ |
| 2022-08-29 | Kreis Leslie W. | Director / 10% Owner | P-Purchase | A | Common Stock | 30,428 | 2.02 | 61.5K | 3,651,528 | — | ↗ |
| 2022-08-29 | Fletcher Aaron G.L. | Director / 10% Owner | P-Purchase | A | Common Stock | 4,660 | 2.02 | 9.4K | 559,076 | — | ↗ |
| 2022-08-26 | Kreis Leslie W. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,377 | 2.01 | 2.8K | 584,784 | — | ↗ |
| 2022-08-26 | Fletcher Aaron G.L. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,306 | 2.01 | 2.6K | 554,416 | — | ↗ |
| 2022-08-26 | Cavu Advisors, LLC | Director | P-Purchase | A | Common Stock | 30,428 | 2.02 | 61.5K | 3,651,528 | — | ↗ |
| 2022-08-17 | Kreis Leslie W. | Director / 10% Owner | P-Purchase | A | Common Stock | 6,142 | 1.93 | 11.9K | 583,407 | — | ↗ |
| 2022-08-17 | Fletcher Aaron G.L. | Director / 10% Owner | P-Purchase | A | Common Stock | 38,035 | 1.93 | 73.4K | 3,612,569 | — | ↗ |
| 2022-08-17 | Cavu Advisors, LLC | Director | P-Purchase | A | Common Stock | 38,035 | 1.93 | 73.4K | 3,612,569 | — | ↗ |
| 2022-08-17 | BIOS Advisors GP, LLC | Director | P-Purchase | A | Common Stock | 38,035 | 1.93 | 73.4K | 3,612,569 | — | ↗ |
| 2022-08-16 | Transcend Partners Opportunity Fund LLC | Director | P-Purchase | A | Common Stock | 789,473 | 1.90 | 1.50M | 4,111,958 | — | ↗ |
| 2022-08-16 | Roemer Alan S. | Director | P-Purchase | A | Common Stock | 26,315 | 1.90 | 50.0K | 55,989 | — | ↗ |
| 2022-08-16 | Rochlin Kate | Officer | P-Purchase | A | Common Stock | 5,263 | 1.90 | 10.0K | 5,263 | — | ↗ |
| 2022-08-16 | McCall Patrick | Officer | P-Purchase | A | Common Stock | 5,263 | 1.90 | 10.0K | 5,263 | — | ↗ |
| 2022-08-16 | Lamb Lawrence | Officer | P-Purchase | A | Common Stock | 526 | 1.90 | 999.40 | 99,730 | — | ↗ |
| 2022-08-16 | Kreis Leslie W. | Director / 10% Owner | P-Purchase | A | Common Stock | 217,891 | 1.90 | 414.0K | 217,891 | — | ↗ |
| 2022-08-16 | Ho William Tai-Wei | Officer | P-Purchase | A | Common Stock | 26,315 | 1.90 | 50.0K | 2,315,745 | — | ↗ |
| 2022-08-16 | Greenwood Luba | Director | P-Purchase | A | Common Stock | 526 | 1.90 | 999.40 | 7,826 | — | ↗ |
| 2022-08-16 | Goswami Trishna | Officer | P-Purchase | A | Common Stock | 2,631 | 1.90 | 5.0K | 2,631 | — | ↗ |
| 2022-08-16 | Fletcher Aaron G.L. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,349,218 | 1.90 | 2.56M | 3,574,534 | — | ↗ |
| 2022-08-16 | Cavu Advisors, LLC | Director | P-Purchase | A | Common Stock | 206,575 | 1.90 | 392.5K | 540,287 | — | ↗ |
| 2022-08-16 | Brandt Peter C. | Director | P-Purchase | A | Common Stock | 105,263 | 1.90 | 200.0K | 182,473 | — | ↗ |
| 2022-08-16 | BIOS Advisors GP, LLC | Director | P-Purchase | A | Common Stock | 206,575 | 1.90 | 392.5K | 540,287 | — | ↗ |
| 2022-06-01 | Whitfill Travis | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 0.00 | — | 10,500 | — | ↗ |
| 2022-06-01 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 0.00 | — | 10,500 | — | ↗ |
| 2022-06-01 | Greenwood Luba | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 0.00 | — | 10,500 | — | ↗ |
| 2022-06-01 | FAIRBAIRN EMILY | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 0.00 | — | 10,500 | — | ↗ |
| 2022-06-01 | Brandt Peter C. | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 0.00 | — | 10,500 | — | ↗ |
| 2022-05-05 | Lamb Lawrence | Officer | M-Exempt | A | Common Stock | 26,204 | 1.07 | 28.0K | 99,204 | — | ↗ |
| 2022-02-15 | Rochlin Kate | Officer | A-Award | A | Employee Stock Option (right to buy) | 96,000 | 4.28 | 410.9K | 96,000 | — | ↗ |
| 2022-02-15 | McCall Patrick | Officer | A-Award | A | Employee Stock Option (right to buy) | 84,500 | 4.28 | 361.7K | 84,500 | — | ↗ |
| 2022-02-15 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 62,500 | 4.28 | 267.5K | 62,500 | — | ↗ |
| 2022-02-15 | Ho William Tai-Wei | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 254,500 | 4.28 | 1.09M | 254,500 | — | ↗ |
| 2022-02-15 | Goswami Trishna | Officer | A-Award | A | Employee Stock Option (right to buy) | 90,500 | 4.28 | 387.3K | 90,500 | — | ↗ |
| 2021-12-01 | Rochlin Kate | Officer | — | D | Employee Stock Option (right to buy) | 41,616 | 5.36 | 223.1K | 0 | — | ↗ |
| 2021-11-19 | Roemer Alan S. | Director | A-Award | A | Stock Option (right to buy) | 86,258 | 6.80 | 586.6K | 86,258 | — | ↗ |
| 2021-11-19 | Goswami Trishna | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 6.80 | 1.70M | 250,000 | — | ↗ |
| 2021-08-13 | Kreis Leslie W. | 10% Owner | J-Other | A | Stock Option (right to buy) | 12,775 | 1.07 | 13.7K | 12,775 | — | ↗ |
| 2021-08-13 | Fletcher Aaron G.L. | 10% Owner | J-Other | A | Stock Option (right to buy) | 12,775 | 1.07 | 13.7K | 12,775 | — | ↗ |
| 2021-08-13 | Bios Equity Partners, LP | 10% Owner | — | I | Stock Option (right to buy) | 12,775 | 1.07 | 13.7K | 0 | — | ↗ |
| 2021-08-03 | Lamb Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 22,082 | 1.07 | 23.6K | 83,582 | — | ↗ |
| 2021-08-03 | Kreis Leslie W. | 10% Owner | C-Conversion | A | Common Stock | 2,225,316 | 0.00 | — | 2,225,316 | — | ↗ |
| 2021-08-03 | Ho William Tai-Wei | Director / Officer | C-Conversion | D | Series A Preferred Stock | 2,792 | 0.00 | — | 0 | — | ↗ |
| 2021-08-03 | Fletcher Aaron G.L. | 10% Owner | C-Conversion | A | Common Stock | 1,876,624 | 0.00 | — | 1,876,624 | — | ↗ |
| 2021-08-03 | FAIRBAIRN EMILY | Director / 10% Owner | C-Conversion | D | Series A Preferred Stock | 2,930,332 | 0.00 | — | 0 | — | ↗ |
| 2021-07-29 | Whitfill Travis | Director | — | D | Stock Option (right to buy) | 12,775 | 1.07 | 13.7K | 0 | — | ↗ |
| 2021-07-29 | Roemer Alan S. | Director | — | D | Stock Option (right to buy) | 225,879 | 6.74 | 1.52M | 0 | — | ↗ |
| 2021-07-29 | McCall Patrick | Officer | — | D | Employee Stock Option (right to buy) | 188,816 | 5.36 | 1.01M | 0 | — | ↗ |
| 2021-07-29 | Lamb Lawrence | Officer | — | D | Employee Stock Option (right to buy) | 273,750 | 6.74 | 1.85M | 0 | — | ↗ |
| 2021-07-29 | Kreis Leslie W. | 10% Owner | — | I | Series A Preferred Stock | 359,374 | 0.00 | — | 0 | — | ↗ |
| 2021-07-29 | Ho William Tai-Wei | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 69,929 | — | ↗ |
| 2021-07-29 | Greenwood Luba | Director | — | D | Common Stock | 0 | 0.00 | — | 7,300 | — | ↗ |
| 2021-07-29 | Fletcher Aaron G.L. | 10% Owner | — | I | Series A Preferred Stock | 359,374 | 0.00 | — | 0 | — | ↗ |
| 2021-07-29 | FAIRBAIRN EMILY | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 8,212 | — | ↗ |
| 2021-07-29 | Brandt Peter C. | Director | — | D | Stock Option (right to buy) | 29,664 | 1.10 | 32.5K | 0 | — | ↗ |
| 2021-07-29 | Beelen Melissa | Officer | — | D | Employee Stock Option (right to buy) | 13,140 | 1.23 | 16.2K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
4.64M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | William Ho Chief Executive Officer | 397.8K | — | — | 210.3K | 336.6K | 9.0K | 953.7K | 22.05% | ↗ |
| 2 | 2025 | Kate Rochlin, Ph.D. President and Chief Operating Officer | 417.9K | — | — | 78.1K | 192.9K | — | 688.9K | 11.34% | ↗ |
| 3 | 2025 | Patrick McCall Chief Financial Officer | 405.0K | — | — | 79.1K | 184.2K | 9.0K | 677.2K | 11.67% | ↗ |
| 4 | 2024 | William Ho Chief Executive Officer | 552.8K | — | — | 888.7K | — | 12.0K | 1.45M | 61.14% | ↗ |
| 5 | 2024 | William Ho President and Chief Executive Officer | 552.8K | — | — | 888.7K | — | 12.0K | 1.45M | 61.14% | ↗ |
| 6 | 2024 | Kate Rochlin, Ph.D. President and Chief Operating Officer | 457.6K | — | — | 329.5K | — | 3.0K | 790.1K | 41.70% | ↗ |
| 7 | 2024 | Kate Rochlin, Ph.D. Chief Operating Officer | 457.6K | — | — | 329.5K | — | 3.0K | 790.1K | 41.70% | ↗ |
| 8 | 2024 | Patrick McCall Chief Financial Officer | 438.3K | — | — | 330.1K | — | 12.0K | 780.4K | 42.29% | ↗ |
| 9 | 2023 | William Ho President and Chief Executive Officer | 572.0K | — | — | 984.2K | 286.0K | 12.0K | 1.85M | 53.08% | ↗ |
| 10 | 2023 | Trishna Goswami, M.D. Chief Medical Officer | 474.0K | — | — | 396.7K | 191.5K | 3.0K | 1.07M | 37.22% | ↗ |
| 11 | 2023 | Patrick McCall Chief Financial Officer | 412.0K | — | — | 323.6K | 167.3K | 12.0K | 914.8K | 35.37% | ↗ |
| 12 | 2022 | William Ho President and Chief Executive Officer | 550.0K | — | — | 892.6K | 275.0K | 12.0K | 1.73M | 51.61% | ↗ |
| 13 | 2022 | Trishna Goswami, M.D. Chief Medical Officer | 452.0K | — | — | 360.8K | 183.5K | 3.0K | 999.3K | 36.10% | ↗ |
| 14 | 2022 | Kate Rochlin, Ph.D. Chief Operating Officer | 400.0K | — | — | 369.3K | 162.4K | 3.0K | 934.7K | 39.51% | ↗ |
| 15 | 2021 | William Ho President and Chief Executive Officer | 446.2K | — | — | 1.56M | 281.3K | — | 2.29M | 68.26% | ↗ |
| 16 | 2021 | Patrick McCall Chief Financial Officer | 339.2K | — | — | 1.03M | 149.3K | — | 1.52M | 67.87% | ↗ |
| 17 | 2021 | Lawrence Lamb, Ph.D. Executive Vice President, Chief Scientific Officer | 326.0K | — | — | 436.3K | 156.5K | — | 918.8K | 47.49% | ↗ |
| 18 | 2020 | Lawrence Lamb, Ph.D. Executive Vice President, Chief Scientific Officer | 245.0K | — | — | 1.31M | 120.0K | — | 1.68M | 78.23% | ↗ |
| 19 | 2020 | William Ho President and Chief Executive Officer | 279.2K | 150.0K | — | 874.5K | 144.0K | — | 1.45M | 60.41% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tai-Wei | Co-Founder, CEO & Director | 743.4K | male |
| Kate Rochlin | President & COO | 610.7K | — |
| Patrick McCall | Chief Financial Officer & Secretary | 598.1K | male |
| Lawrence S. Lamb | Executive Vice President, Co-Founder & Chief Scientific Officer | 482.5K | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INAB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
